Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Viswanathan Ramakrishnan

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
Breast Cancer Research and Treatment|April 12, 2011
A signature of immune function genes associated with recurrence-free survival in breast cancer patientsMaria Libera Ascierto, Maciej Kmieciak, Michael O Idowu, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|December 6, 2011
Evaluation of the effect of ammonia on nicotine pharmacokinetics using rapid arterial samplingDiana L McKinney, Maria Gogova, Bruce D Davies, et al.
Trials|April 13, 2022
Effect of novel training to normalize altered finger force direction post-stroke: study protocol for a double-blind randomized controlled trialNa Jin Seo, Derek G Kamper, Viswanathan Ramakrishnan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphomaJohn D Roberts, Mitchell R Smith, Eric J Feldman, et al.
Physical Therapy|January 29, 2019
TheraBracelet Stimulation During Task-Practice Therapy to Improve Upper Extremity Function After Stroke: A Pilot Randomized Controlled StudyNa J Seo, Michelle L Woodbury, Leonardo Bonilha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2003
Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivoAdly Yacoub, Clint Mitchell, Andrea Lister, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2Beata Holkova, Jeffrey G Supko, Matthew M Ames, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2011
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasmsBeata Holkova, E Brent Perkins, Viswanathan Ramakrishnan, et al.
The Lancet. Neurology|March 29, 2025
Safety and efficacy of transcranial direct current stimulation in addition to constraint-induced movement therapy for post-stroke motor recovery (TRANSPORT2): a phase 2, multicentre, randomised, sham-controlled triple-blind trialGottfried Schlaug, Christy Cassarly, Jody A Feld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2014
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasmsBeata Holkova, Maciej Kmieciak, E Brent Perkins, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Breast Cancer Research and Treatment|April 12, 2011
A signature of immune function genes associated with recurrence-free survival in breast cancer patientsMaria Libera Ascierto, Maciej Kmieciak, Michael O Idowu, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|December 6, 2011
Evaluation of the effect of ammonia on nicotine pharmacokinetics using rapid arterial samplingDiana L McKinney, Maria Gogova, Bruce D Davies, et al.
Trials|April 13, 2022
Effect of novel training to normalize altered finger force direction post-stroke: study protocol for a double-blind randomized controlled trialNa Jin Seo, Derek G Kamper, Viswanathan Ramakrishnan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2006
Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphomaJohn D Roberts, Mitchell R Smith, Eric J Feldman, et al.
Physical Therapy|January 29, 2019
TheraBracelet Stimulation During Task-Practice Therapy to Improve Upper Extremity Function After Stroke: A Pilot Randomized Controlled StudyNa J Seo, Michelle L Woodbury, Leonardo Bonilha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2003
Melanoma differentiation-associated 7 (interleukin 24) inhibits growth and enhances radiosensitivity of glioma cells in vitro and in vivoAdly Yacoub, Clint Mitchell, Andrea Lister, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2013
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2Beata Holkova, Jeffrey G Supko, Matthew M Ames, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2011
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasmsBeata Holkova, E Brent Perkins, Viswanathan Ramakrishnan, et al.
The Lancet. Neurology|March 29, 2025
Safety and efficacy of transcranial direct current stimulation in addition to constraint-induced movement therapy for post-stroke motor recovery (TRANSPORT2): a phase 2, multicentre, randomised, sham-controlled triple-blind trialGottfried Schlaug, Christy Cassarly, Jody A Feld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2014
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasmsBeata Holkova, Maciej Kmieciak, E Brent Perkins, et al.
Pageof 13